Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | GLA | P06280 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3073456 | 0.86 | ALDH1A1 (0.52) | SMN1; SMN2ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL13139917 | 0.85 | CA12 (0.50) | SMN1; SMN2ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL16563455 | 0.85 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL3074755 | 0.84 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL3077982 | 0.84 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL24369481 | 0.84 | HTT (0.53) | SMN1; SMN2ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL30935665 | 0.84 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL22228625 | 0.83 | SMN1; SMN2 (0.45) | SMN1; SMN2ALDH1A1KDM4EHSD17B10HPGD | |
| Hydrochloric Acid SCHEMBL26603916 | 0.83 | ALDH1A1 (0.48) | SMN1; SMN2ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL3084426 | 0.83 | EPHB3 (0.54) | SMN1; SMN2ALDH1A1KDM4EHSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113773335-B | Compound serving as protein kinase inhibitor and preparation method and application thereof | 成都海博为药业有限公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-113773335-A | Compound as protein kinase inhibitor and preparation method and application thereof | 成都海博为药业有限公司 | 2021-12-10 | — | — | CN | disclosed |
| CN-112110938-B | Compound as protein kinase inhibitor and preparation method and application thereof | 成都海博为药业有限公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-112110938-A | Compound as protein kinase inhibitor and preparation method and application thereof | 成都海博为药业有限公司 | 2020-12-22 | — | — | CN | disclosed |
| EP-2678338-B1 | PYRAZOLO[1,5-A]PYRIDINES AS TRK INHIBITORS | NOVARTIS AG (CH) | 2015-09-09 | — | — | EP | disclosed |
| EP-2678338-B1 | PYRAZOLO[1,5-A]PYRIDINES AS TRK INHIBITORS | NOVARTIS AG (CH) | 2015-09-09 | — | — | EP | disclosed |
| US-9102671-B2 | Compounds and compositions as TRK inhibitors | NOVARTIS AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-9102671-B2 | Compounds and compositions as TRK inhibitors | NOVARTIS AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-9102671-B2 | Compounds and compositions as TRK inhibitors | NOVARTIS AG (CH) | 2015-08-11 | — | — | US | disclosed |
| EP-2678338-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2014-01-01 | — | — | EP | disclosed |
| US-20130331397-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2013-12-12 | — | — | US | disclosed |
| WO-2012116217-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-08-30 | — | — | WO | disclosed |
| WO-2012116217-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-08-30 | — | — | WO | disclosed |
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-09-09 | — | — | US | disclosed |
| EP-2176260-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009008748-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331397-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | CNKSR1, BMP2K, RAF1 | SMN1; SMN2 1172/4885ALDH1A1 4150/4885KDM4E 1511/4885 |
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | TP53, PNPO, DPYD | SMN1; SMN2 3214/4885ALDH1A1 588/4885KDM4E 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.